MRD
13
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (13)
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML